Premium
Clinical Trial of low ‐ Dose Oral Contraceptive Pill Containing 0.75mg. Lynestrenol and 0.0375mg. Ethinyl Estradiol
Author(s) -
Koetsawang Suporn,
Srisupandit Suwanee
Publication year - 1977
Publication title -
the journal of the asian federation of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0377-0532
DOI - 10.1111/j.1447-0756.1977.tb00347.x
Subject(s) - nausea , medicine , breakthrough bleeding , menstrual cycle , metrorrhagia , lynestrenol , incidence (geometry) , gynecology , pill , ethinylestradiol , clinical research , obstetrics , physiology , population , research methodology , pharmacology , family planning , hormone , mathematics , geometry , environmental health
SUMMARY The combination of 0.75 mg lynestre‐nol and 0.0375 mg ethinyl estradiol was administered to 100 women for a total of 998 cycles. There were no pregnancies. In the first treatment cycle, breakthrough bleeding and/or spotting occurred in 24% of cases, but this decreased rapidly to less than 5% after the third cycle. The incidence of “missed period” was 17% in the first cycle but decreased to less than 10% after the second. During the first cycle mild nausea occurred in 16% of the women but again this dropped sharply after the second cycle. The pereentage of other side effects was remarkably low. Clinical study with this low dose combination indicates that it is as effective as the traditional dose combination and for metabolic reasons, therefore, it is the method to be preferred.